Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Siramesine (Formerly known as Lu-28-179) is a potent and selective agonist of sigma-2 receptor. Siramesine is able to trigger cancer cell death through destabilisation of mitochondria and exhibit promising anticancer activity in vivo. In HaCaT cells, cell death was accompanied by caspase activation, rapid loss of mitochondrial membrane potential (MMP), cytochrome c release, cardiolipin peroxidation and typical apoptotic morphology, whereas in U-87MG cells most apoptotic hallmarks were not notable, although MMP was rapidly lost.
ln Vitro |
IC50 (sigma 1) = 17 nM, IC50 (sigma 2) = 0.12 nM, IC50 (5-HT1A) = 21000 nM, IC50 (5-HT1A) = 2000 nM, IC50 (D2) = 800 nM, and IC50 (alpha 1) = 330 nM are the binding affinities displayed by siramesine[1]. In different cell lines (HaCaT, Hsc-4, HeLa, and MCF-7, neuroblastoma cell line SH-SY5Y, and glioblastoma cell line U-87MG), siramesine (0-50μM; 8 hours) promotes cell death[2]. In HaCaT and U-87MG cells, siramesine (0–40 μM; 2-48 hours) activates caspases[2].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
|
||
Additional Infomation |
Drug Indication
Investigated for use/treatment in anxiety disorders. |
Molecular Formula |
C30H31FN2O
|
|
---|---|---|
Molecular Weight |
454.59
|
|
Exact Mass |
454.242
|
|
CAS # |
147817-50-3
|
|
Related CAS # |
Siramesine hydrochloride;224177-60-0;Siramesine fumarate;163630-79-3
|
|
PubChem CID |
9829526
|
|
Appearance |
Typically exists as solid at room temperature
|
|
Density |
1.2±0.1 g/cm3
|
|
Boiling Point |
611.4±55.0 °C at 760 mmHg
|
|
Flash Point |
323.6±31.5 °C
|
|
Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
|
Index of Refraction |
1.629
|
|
LogP |
9.19
|
|
Hydrogen Bond Donor Count |
0
|
|
Hydrogen Bond Acceptor Count |
3
|
|
Rotatable Bond Count |
6
|
|
Heavy Atom Count |
34
|
|
Complexity |
656
|
|
Defined Atom Stereocenter Count |
0
|
|
SMILES |
FC1=CC=C(N2C=C(CCCCN3CCC4(CC3)OCC5=C4C=CC=C5)C6=C2C=CC=C6)C=C1
|
|
InChi Key |
XWAONOGAGZNUSF-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2
|
|
Chemical Name |
1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1998 mL | 10.9989 mL | 21.9978 mL | |
5 mM | 0.4400 mL | 2.1998 mL | 4.3996 mL | |
10 mM | 0.2200 mL | 1.0999 mL | 2.1998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effect of siramesine on viability of various cell lines.Cell Death Dis.2013 Oct 3;4:e818. th> |
---|
Effect of siramesine on mitochondria.Cell Death Dis.2013 Oct 3;4:e818. td> |
ROS generation in siramesine-induced cell death.Cell Death Dis.2013 Oct 3;4:e818. td> |